You are viewing the site in preview mode
Skip to main content
|
Characteristics
|
HR+/HER2− (n = 594)
|
HR+/HER2+ (n = 120)
|
HR−/HER2+ (n = 75)
|
HR−/HER2− (n = 201)
|
Unknown (n = 109)
|
P
|
|---|
|
BC family history
| | | | | |
0.023
|
|
YES
|
62 (10.4)
|
16 (13.3)
|
5 (6.7)
|
21 (10.4)
|
9 (8.3)
| |
|
NO
|
524 (88.2)
|
104 (86.7)
|
68 (90.7)
|
179 (89.1)
|
94 (86.2)
| |
|
Unknown
|
8 (1.3)
|
0 (0)
|
2 (2.7)
|
1 (0.5)
|
6 (5.5)
| |
|
Reproductive history
| | | | | |
0.003
|
|
YES
|
451 (75.9)
|
92 (76.7)
|
61 (81.3)
|
146 (72.6)
|
77 (70.6)
| |
|
NO
|
136 (22.9)
|
28 (23.3)
|
12 (16.0)
|
55 (27.4)
|
26 (23.9)
| |
|
Unknown
|
7 (1.2)
|
0 (0)
|
2 (2.7)
|
0 (0)
|
6 (5.5)
| |
|
Breastfeeding history
| | | | | |
< 0.001
|
|
YES
|
410 (69.0)
|
79 (65.8)
|
59 (78.7)
|
128 (63.7)
|
69 (63.3)
| |
|
NO
|
177 (29.8)
|
41 (34.2)
|
14 (18.7)
|
72 (35.8)
|
33 (30.3)
| |
|
Unknown
|
7 (1.2)
|
0 (0)
|
2 (2.7)
|
1 (0.5)
|
7 (6.4)
| |
|
Tumor size
| | | | | |
0.007
|
|
T1
|
250 (42.1)
|
39 (32.5)
|
17 (22.7)
|
69 (34.3)
|
45 (41.3)
| |
|
T2
|
261 (43.9)
|
61 (50.8)
|
40 (53.3)
|
103 (51.2)
|
43 (39.4)
| |
|
T3
|
45 (7.6)
|
10 (8.3)
|
8 (10.7)
|
12 (6.0)
|
13 (11.9)
| |
|
T4
|
3 (0.5)
|
5 (4.2)
|
3 (4.0)
|
4 (2.0)
|
1 (0.9)
| |
|
Tx
|
35 (5.9)
|
5 (4.2)
|
7 (9.3)
|
13 (6.5)
|
7 (6.4)
| |
|
Stage
| | | | | |
< 0.001
|
|
I
|
166 (27.9)
|
27 (22.5)
|
8 (10.7)
|
48 (23.9)
|
33 (30.3)
| |
|
II a
|
199 (33.5)
|
40 (33.3)
|
26 (34.7)
|
90 (44.8)
|
28 (25.7)
| |
|
II b
|
85 (14.3)
|
16 (13.3)
|
13 (17.3)
|
28 (13.9)
|
17 (15.6)
| |
|
III a
|
72 (12.1)
|
15 (12.5)
|
12 (16.0)
|
17 (8.5)
|
10 (9.2)
| |
|
III b
|
2 (0.3)
|
1 (0.8)
|
2 (2.7)
|
3 (1.5)
|
0 (0)
| |
|
III c
|
48 (8.1)
|
17 (14.2)
|
12 (6.0)
|
4 (2.0)
|
16 (14.7)
| |
|
Unknown
|
22 (3.7)
|
4 (3.3)
|
2 (2.7)
|
11 (5.5)
|
5 (4.6)
| |
|
LN metastasis
| | | | | |
< 0.001
|
|
N0
|
312 (52.5)
|
55 (45.8)
|
36 (48.0)
|
134 (66.7)
|
48 (44.0)
| |
|
N1
|
161 (27.1)
|
30 (25.0)
|
14 (18.7)
|
46 (22.9)
|
25 (22.9)
| |
|
N2
|
70 (11.8)
|
16 (13.3)
|
13 (17.2)
|
16 (8.0)
|
9 (8.3)
| |
|
N3
|
46 (7.7)
|
17 (14.2)
|
12 (16.0)
|
2 (1.0)
|
17 (15.6)
| |
|
Unknown
|
5 (0.8)
|
2 (1.7)
|
0 (0)
|
3 (1.5)
|
10 (9.2)
| |
|
Histological grade
| | | | | |
< 0.001
|
|
Well
|
29 (4.9)
|
0 (0)
|
1 (1.3)
|
2 (1.0)
|
3 (2.8)
| |
|
Moderately
|
371 (62.5)
|
67 (55.8)
|
36 (48.0)
|
78 (38.8)
|
42 (38.5)
| |
|
Poorly
|
50 (8.4)
|
25 (20.8)
|
16 (21.3)
|
52 (25.9)
|
20 (18.3)
| |
|
Unknown
|
144 (24.2)
|
28 (23.3)
|
22 (29.3)
|
69 (34.3)
|
44 (40.4)
| |
|
Pathological type
| | | | | |
0.906
|
|
IDC
|
534 (89.9)
|
110 (91.7)
|
71 (94.7)
|
183 (91.0)
|
101 (92.7)
| |
|
IBC
|
7 (1.2)
|
1 (0.8)
|
0 (0)
|
1 (0.5)
|
1 (0.9)
| |
|
Others
|
53 (8.9)
|
9 (7.5)
|
4 ( (5.3)
|
17 (8.5)
|
7 (6.4)
| |
|
Final surgery
| | | | | |
0.002
|
|
BCS
|
143 (24.1)
|
19 (15.8)
|
14 (18.7)
|
64 (31.8)
|
17 (15.6)
| |
|
Mastectomy
|
451 (75.9)
|
101 (84.2)
|
61 (81.3)
|
137 (68.2)
|
92 (84.4)
| |
|
NACT
| | | | | |
0.003
|
|
YES
|
80 (13.5)
|
19 (15.8)
|
23 (30.7)
|
33 (16.4)
|
21 (19.3)
| |
|
NO
|
514 (86.5)
|
101 (84.2)
|
52 (69.3)
|
168 (83.6)
|
88 (80.7)
| |
|
ACT
| | | | | |
0.046
|
|
A-based
|
72 (12.1)
|
17 (14.2)
|
12 (16.0)
|
24 (11.9)
|
15 (13.8)
| |
|
A- and T-based
|
490 ( (82.5)
|
97 (80.8)
|
58 (77.3)
|
162 (80.6)
|
77 (70.6)
| |
|
Unknown
|
28 (4.7)
|
6 (5.0)
|
5 (6.7)
|
12 (6.0)
|
16 (14.7)
| |
|
None
|
4 (0.7)
|
0 (0)
|
0 (0)
|
3 (1.5)
|
1 (0.9)
| |
|
Radiotherapy
| | | | | |
< 0.001
|
|
YES
|
304 (51.2)
|
59 (49.2)
|
46 (61.3)
|
105 (52.2)
|
43 (39.4)
| |
|
NO
|
254 (42.8)
|
52 (43.3)
|
24 (32.0)
|
85 (42.3)
|
38 (34.9)
| |
|
Unknown
|
36 (6.1)
|
9 (7.5)
|
5 (6.7)
|
11 (5.5)
|
28 (25.7)
| |
|
ET
| | | | | |
< 0.001
|
|
YES
|
467 (78.6)
|
89 (74.2)
|
0 (0)
|
0 (0)
|
33 (30.3)
| |
|
NO
|
27 (4.5)
|
8 (6.7)
|
70 (93.3)
|
194 (96.5)
|
17 (15.6)
| |
|
Unknown
|
100 (16.8)
|
23 (19.2)
|
5 (6.7)
|
7 (3.5)
|
59 (54.1)
| |
|
OFS
| | | | | |
< 0.001
|
|
YES
|
147 (24.7)
|
34 (28.3)
|
0 (0)
|
0 (0)
|
6 (5.5)
| |
|
NO
|
215 (36.2)
|
46 (38.3)
|
67 (89.3)
|
189 (94.0)
|
28 (25.7)
| |
|
Unknown
|
232 (39.1)
|
40 (33.3)
|
8 (10.7)
|
12 (6.0)
|
75 (68.8)
| |
|
TT
| | | | | |
< 0.001
|
|
YES
|
2 (0.3)
|
51 (42.5)
|
32 (42.7)
|
0 (0)
|
0 (0)
| |
|
NO
|
553 (93.1)
|
41 (34.2)
|
23 (30.7)
|
195 (97.0)
|
24 (22.0)
| |
|
Unknown
|
39 (6.6)
|
28 (23.3)
|
20 (26.7)
|
6 (3.0)
|
85 (78.0)
| |
- All data are given as No. of patients (%). None represents no chemotherapy has been adopted
- LN, lymph node; IDC, invasive ductal carcinoma; IBC, invasive lobular carcinoma; NACT, neoadjuvant chemotherapy; BCS, breast conserving surgery; A-based, anthracycline-based; A- and T-based, anthracycline- and taxane-based; OFS, ovarian function suppression; ET, endocrine therapy; TT, trastuzumab therapy
